Home · BioPulse

Investment TrendsMay 4, 2026

Boehringer's Dual-Action Obesity Drug Clears Phase III — And The Field Is Taking Notice

Investment TrendsMay 4, 2026

China's Biotech Licensing Boom Reaches a New Inflection Point

License-out deals from China-based biotechs reached a record $137.7 billion in 2025. With average deal size up 76% and upfront fees doubling, global pharma is treating China's pipeline as essential infrastructure.

Drug DevelopmentMay 4, 2026

KIR-CAR T Cells Signal a New Era for Solid Tumor Immunotherapy

First-in-human data for KIR-CAR therapy show encouraging safety and early efficacy in ovarian cancer, mesothelioma, and cholangiocarcinoma — a milestone for cell therapy in solid tumors.

Investment TrendsMay 4, 2026

Pharma M&A Surges Back in 2026 — Here Is What the Data Shows

With $116 billion in biopharma deals in 2025 and a record $228.4 billion in global biotech M&A, 2026 is shaping up as a landmark year for deal-making. Big Pharma is spending big — and the drivers go beyond patent cliffs.

Drug DevelopmentMay 2, 2026

Boehringer's Dual-Action Obesity Drug Clears Phase III — And The Field Is Taking Notice

Investment TrendsMay 4, 2026

China's Biotech Licensing Boom Reaches a New Inflection Point

Drug DevelopmentMay 4, 2026

KIR-CAR T Cells Signal a New Era for Solid Tumor Immunotherapy

First-in-human data for KIR-CAR therapy show encouraging safety and early efficacy in ovarian cancer, mesothelioma, and cholangiocarcinoma — a milestone for cell therapy in solid tumors.

Investment TrendsMay 4, 2026

Pharma M&A Surges Back in 2026 — Here Is What the Data Shows

Drug DevelopmentMay 2, 2026

BioPulse

First-hand insights and deep analysis of the biotech & pharma industry

China's Biotech Licensing Boom Reaches a New Inflection Point

KIR-CAR T Cells Signal a New Era for Solid Tumor Immunotherapy

Pharma M&A Surges Back in 2026 — Here Is What the Data Shows

Boehringer's Dual-Action Obesity Drug Clears Phase III — And The Field Is Taking Notice

China's Biotech Licensing Boom Reaches a New Inflection Point

KIR-CAR T Cells Signal a New Era for Solid Tumor Immunotherapy

Pharma M&A Surges Back in 2026 — Here Is What the Data Shows

Boehringer's Dual-Action Obesity Drug Clears Phase III — And The Field Is Taking Notice

China's Biotech Licensing Boom Reaches a New Inflection Point

KIR-CAR T Cells Signal a New Era for Solid Tumor Immunotherapy

Pharma M&A Surges Back in 2026 — Here Is What the Data Shows

Boehringer's Dual-Action Obesity Drug Clears Phase III — And The Field Is Taking Notice